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Abstract
Background: Hypertensive disorders in pregnancy are leading causes of maternal, fetal and
neonatal morbidity and mortality worldwide. However, studies attempting to quantify the effect of
hypertension on adverse perinatal outcomes have been mostly conducted in tertiary centres. This
population-based study explored the frequency of hypertensive disorders in pregnancy and the
associated increase in small for gestational age (SGA) and stillbirth.
Methods: We used information on all pregnant women and births, in the Canadian province of
Nova Scotia, between 1988 and 2000. Pregnancies were excluded if delivery occurred < 20 weeks,
if birthweight was < 500 grams, if there was a high-order multiple pregnancy (greater than twin
gestation), or a major fetal anomaly.
Results: The study population included 135,466 pregnancies. Of these, 7.7% had mild pregnancy-
induced hypertension (PIH), 1.3% had severe PIH, 0.2% had HELLP (hemolysis, elevated liver
enzymes, low platelets), 0.02% had eclampsia, 0.6% had chronic hypertension, and 0.4% had chronic
hypertension with superimposed PIH. Women with any hypertension in pregnancy were 1.6 (95%
CI 1.5–1.6) times more likely to have a live birth with SGA and 1.4 (95% CI 1.1–1.8) times more
likely to have a stillbirth as compared with normotensive women. Adjusted analyses showed that
women with gestational hypertension without proteinuria (mild PIH) and with proteinuria (severe
PIH, HELLP, or eclampsia) were more likely to have infants with SGA (RR 1.5, 95% CI 1.4–1.6 and
RR 3.2, 95% CI 2.8–3.6, respectively). Women with pre-existing hypertension were also more likely
to give birth to an infant with SGA (RR 2.5, 95% CI 2.2–3.0) or to have a stillbirth (RR 3.2, 95% CI
1.9–5.4).
Conclusions: This large, population-based study confirms and quantifies the magnitude of the
excess risk of small for gestational age and stillbirth among births to women with hypertensive
disease in pregnancy.
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Background
Hypertensive disorders in pregnancy complicate approxi-
mately 10–16% of pregnancies and are leading causes of
maternal, fetal and neonatal morbidity and mortality
worldwide [1-3]. Definitions, classifications, assessment
and management of hypertensive disorders vary consider-
ably in the literature and from country to country [4]:
thus, it is difficult to compare results from different stud-
ies. Past studies have attempted to quantify the effect of
hypertension on adverse perinatal outcomes. To date, the
majority of study designs have included retrospective and
prospective cohort studies [5-9,12-20], as well as rand-
omized-controlled trials that assessed the impact of anti-
hypertensive medication on maternal and perinatal
outcomes[10,11]. For the most part, these studies have
been concentrated in tertiary referral centres, and suggest
that hypertension in pregnancy leads to an increased risk
of small for gestational age (SGA) and preterm birth.
We, therefore, carried out a population-based study to
quantify the frequency of hypertensive disorders in preg-
nancy and also the excess risk of SGA and stillbirth that is
associated with this pregnancy complication. We investi-
gated the way in which SGA and stillbirth were modified
by other factors that also have a serious influence on SGA
and stillbirth, for example, whether a twin gestation mod-
ifies the effect of hypertension on SGA, or whether smok-
ing modifies the effect of hypertension on stillbirth.
Methods
Population
The study population included all births to residents of
the province of Nova Scotia, Canada between 1988 and
2000. Information on these births was obtained from the
Nova Scotia Atlee Perinatal Database. The Nova Scotia
Atlee Perinatal Database includes several hundred varia-
bles containing maternal and newborn information, such
as demographic variables, procedures, interventions,
maternal and newborn diagnoses and morbidity and
mortality information for every pregnancy and birth
occurring in Nova Scotia hospitals and to Nova Scotia res-
idents since 1988.
Pregnancies were excluded if delivery occurred < 20
weeks, if birthweight was < 500 g, if there was a higher
order pregnancy (greater than twin gestation), or a known
major fetal anomaly. Information in the database on the
type of hypertensive disorder is directly coded from med-
ical charts. The diagnosis of hypertensive disorders in
pregnancy was made if it occurred in the antepartum or
postpartum period. Mild pregnancy induced hyperten-
sion (PIH) included physician-diagnosed mild pregnancy
induced hypertension if in the chart, transient hyperten-
sion or a diastolic blood pressure exceeding 90 mmHg on
two or more occasions in a 24-hour period. Severe preg-
nancy induced hypertension included physician-diag-
nosed severe pregnancy induced hypertension, diastolic
blood pressure ≥ 110 mm Hg on at least two occasions
within a 6-hour period, if magnesium sulfate was admin-
istered for seizure prophylaxis, if there was ≥ 2+ proteinu-
ria, low platelets (<100,000), and/or elevated liver
enzymes (ALT > 35 u/L, AST > 30 u/L and/or LDH > 670
u/L). HELLP syndrome (hemolysis, elevated liver
enzymes, low platelets) included physician-diagnosed
HELLP. Eclampsia included physician-diagnosed eclamp-
sia or one or more convulsions not attributable to other
cerebral conditions such as epilepsy or cerebral hemor-
rhage in a patient with hypertension. Chronic hyperten-
sive disease included a history of hypertensive disease
when not pregnant, prior to current pregnancy or prior to
20 weeks of the current pregnancy. Pregnancy induced
hypertension superimposed on chronic hypertension
included physician-diagnosed pregnancy induced hyper-
tension superimposed on chronic hypertension or if there
was hemolysis, elevated liver enzymes or low platelets.
We first examined the maternal characteristics of study
subjects with hypertension in pregnancy. For this analysis,
hypertensive disorders in pregnancy were defined accord-
ing to Nova Scotia Atlee Perinatal Database definitions:
mild PIH, severe PIH, HELLP, eclampsia, chronic hyper-
tension and chronic hypertension with superimposed
PIH. Maternal characteristics which were considered
included age, marital status, parity, prepregnancy weight,
pregnancy weight gain, administration of antenatal ster-
oids, smoking, drug abuse, the presence of anemia (Hgb <
10 gm%), gestational diabetes (two abnormal values on a
glucose tolerance test in pregnancy or if insulin was
administered for the first time in pregnancy), pre-existing
diabetes, and twin gestation.
For the multivariate analyses, these database definitions
were grouped to more closely approximate commonly
used definitions such as those proposed by the Canadian
Hypertensive Society and other international organiza-
tions [4]. These groups were defined as gestational hyper-
tension without proteinuria (including the database
entity mild pregnancy induced hypertension), gestational
hypertension with proteinuria (including the database
entities severe pregnancy induced hypertension, HELLP,
and eclampsia) and pre-existing hypertension (including
the database entities chronic hypertension and chronic
hypertension with superimposed pregnancy induced
hypertension).
Only live births were considered in the analysis of small
for gestational age, while all births were considered for the
stillbirth analyses. Small for gestational age was defined as
birthweight for gestational age that was less than the sex-
specific 10th percentile cut-off of a recently publishedBMC Pregnancy and Childbirth 2004, 4:17 http://www.biomedcentral.com/1471-2393/4/17
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Canadian fetal growth reference [21]. Stillbirth was
defined as fetal death before birth, with gestational age ≥
20 weeks and birthweight ≥ 500 grams.
Ethical approval for the study was obtained from the
Research Ethics Boards at Dalhousie University in Halifax,
Nova Scotia, the Reproductive Care Program of Nova Sco-
tia and the IWK Health Centre in Halifax, Nova Scotia.
Statistical analysis
Exact binomial 95% confidence intervals were calculated
for rates of hypertensive disorders in pregnancy. Descrip-
tive analyses were carried out on maternal data to ascer-
tain the association between maternal characteristics and
hypertensive disorders in pregnancy. Categorical data
between hypertensive and normotensive pregnancies
were compared using chi-square and Fisher's exact tests,
where appropriate.
Logistic regression analyses were carried out to determine
the adjusted odds ratios (OR) and 95% confidence inter-
vals (CI) expressing the relationship between any hyper-
tensive disorder in pregnancy and groups of hypertension
(i.e., gestational hypertension without proteinuria, gesta-
tional hypertension with proteinuria, pre-existing hyper-
tension) and the two dichotomous primary outcomes
(SGA and stillbirth). Backward stepwise elimination of
variables was carried out to identify all significant deter-
minants of the outcome. Modification of the effect of
hypertensive disorders on SGA or stillbirth was investi-
gated, based on clinical understanding. Variables consid-
ered to be in the causal pathway between the determinant
and the outcome (e.g., SGA in the analysis of stillbirth)
were not adjusted for in the model [22-24]. When the out-
come rate was low we assumed the odds ratio was equal
to the relative risk, but not in situations when the out-
come rate was high (>10 percent). The significance level
selected was P < .05 and all tests were two-tailed. Statisti-
cal analyses were performed using the SAS programming
package for Windows (Version 8.0).
Results
Frequency of hypertensive disease
The study population included 135,466 pregnancies. Of
these, 7.7% (95% CI 7.6,7.9) had mild PIH, 1.3% (95%
CI 1.3,1.4) had severe PIH, 0.2% (95% CI 0.1,0.2) had
HELLP, 0.02% (95% CI 0.02,0.03) had eclampsia, 0.6%
(95% CI 0.5,0.6) had chronic hypertension and 0.4%
(95% CI 0.3,0.4) had chronic hypertension with superim-
posed PIH. The overall rate of hypertensive disease in
pregnancy was 10.1% (95% CI 10.0,10.3).
Maternal characteristics
Table 1 summarizes the characteristics of women with
hypertensive disorders in pregnancy from 1988–2000.
Women with severe PIH were less likely to be married
(63.5%), while women with chronic hypertension (with
or without superimposed PIH) were more likely to be
married (83.2% and 77.3%, respectively) compared with
normotensive women (69.6%). Women with hyperten-
sive disorders were more likely to be nulliparous (range
42.2% to 78.2%) as compared with normotensive women
(41.9%). Women with hypertensive disorders in preg-
nancy had higher pre-pregnancy weight (range 66.8 kg to
82.0 kg) compared with normotensive women (64.4 kg).
While women with PIH (mild or severe) had on average a
greater weight gain in pregnancy (16.2 kg and 16.5 kg,
respectively), women with chronic hypertension (with or
without superimposed PIH) had a lower weight gain
(12.2 kg and 13.2 kg, respectively) compared with normo-
tensive women (14.4 kg). A smaller proportion of women
with hypertensive disorders in pregnancy smoked (range
13.0% to 22.7%) as compared with normotensive women
(30.7%). Women with hypertensive disorders in preg-
nancy were more likely to have gestational diabetes (range
4.6% to 9.1%) and pre-existing diabetes (range 0.8% to
2.5%) compared with normotensive women (2.3% and
0.3%, respectively). Twin pregnancies were more likely to
be complicated by hypertensive disorders (range 2.3% to
6.4%) as compared with normotensive pregnancies
(1.0%).
Small for gestational age
Table 2 summarizes the crude relationships between
hypertension in pregnancy and SGA. There was an
increased risk of SGA among infants born to women with
any hypertensive disorder (RR 1.6, 95% CI 1.5,1.6) com-
pared with infants born to women with normotensive
pregnancies. There was an increased risk of SGA among
infants born to women with mild PIH (RR 1.3, 95% CI
1.3,1.4), severe PIH (RR 2.5, 95% CI 2.3,2.8), HELLP (RR
3.8, 95% CI 3.2,4.5), eclampsia (RR 3.5, 95% CI 2.2,5.7),
chronic hypertension (RR 1.4, 95% CI 1.1,1.6) and
chronic hypertension with PIH (RR 2.2, 95% CI 1.8,2.6)
compared with infants born to women with normoten-
sive pregnancies.
After controlling for potential confounders, women with
any hypertensive disorder were 1.8 (95% CI 1.7,1.9, P <
.001) times more likely to have a live birth with SGA as
compared with normotensive women. Women with ges-
tational hypertension without proteinuria were 1.5 (95%
CI 1.4,1.6, P < .001) times more likely to have a live birth
with SGA as compared with normotensive women. Simi-
larly, women with gestational hypertension with pro-
teinuria were 3.3 (95% CI 3.0,3.9, P < .001) times more
likely and women with pre-existing hypertension were 2.5
(95% CI 2.1,2.9, P < .001) times more likely to have a live
birth with SGA as compared with normotensive women.BMC Pregnancy and Childbirth 2004, 4:17 http://www.biomedcentral.com/1471-2393/4/17
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Table 1: Characteristics of women with and without hypertensive disorders in pregnancy, Nova Scotia, 1988–2000.
Variable Normotensive
n = 121,760
Mild PIH
n = 10,460
Severe PIH
n = 1,770
HELLP
n = 202
Eclampsia
n = 32
Chronic HTN
n = 767
Chronic HTN
+PIH n = 475
Mean age in years (SD) 27.8 (5.3) 27.5 (5.4)* 26.9 (5.7)* 28.9 (5.5)* 25.6 (6.8)* 31.1 (5.0)* 30.5 (5.1)*
Married (%) 84,739 (69.6) 7,530 (72.0) 1,124 (63.5)* 145 (71.8) 18 (56.3) 638 (83.2)* 367 (77.3)*
Nulliparous (%) 51,057 (41.9) 6,760 (64.6)* 1,328 (75.0)* 158 (78.2)* 20 (62.5)* 324 (42.2)* 259 (54.5)*
Mean prepregnancy weight in kg 
(SD)
64.4 (13.8) 70.6 (16.7)* 67.6 (15.6)* 66.8 (16.0)* 68.2 (16.9) 82.0 (20.9)* 81.3 (20.9)*
Mean weight gain in kg (SD) 14.4 (6.0) 16.2 (6.9)* 16.5 (6.9)* 14.8 (7.0) 16.2 (6.2) 12.2 (6.7)* 13.2 (7.3)*
Smokes any cigarettes (%) 35,846 (30.7) 2,157 (21.5)* 376 (22.7)* 31 (16.0)* 6 (21.4) 150 (20.4)* 59 (13.0)*
Anemia (%) 3,441 (2.8) 242 (2.3)* 78 (4.3)* 15 (7.4)* 0 (0) 31 (4.1) 20 (4.2)
Gestational Diabetes (%) 2,749 (2.3) 485 (4.6)* 84 (4.8)* 3 (1.5) 2 (6.3) 70 (9.1)* 34 (7.2)*
Preexisting Diabetes (%) 331 (0.3) 85 (0.8)* 29 (1.6)* 4 (2.0)* 0 (0) 19 (2.5)* 9 (1.9)*
Anti-hypertensive medication (%) 0 (0) 107 (1.0) 97 (5.5) 23 (11.4) 5 (15.6) 146 (19.0) 122 (25.7)
Twins (%) 1,231 (1.0) 244 (2.3)* 60 (3.4)* 13 (6.4)* 0 (0) 7 (0.9) 13 (2.7)*
PIH denotes pregnancy induced hypertension, HELLP denotes hemolysis, elevated liver enzymes, low platelets syndrome, HTN denotes 
hypertension. * Denotes hypertension categories significantly different from the normotensive category.
Table 2: Comparison of small for gestational age (SGA, <10th percentile) rates among live births to hypertensive vs. normotensive 
women, Nova Scotia, 1988–2000.
Total No. SGA Relative Risk 95% CI P value
No. %
Normotensive women 122,394 12,032 9.8 1.0 - -
All hypertensive women 13,940 2,131 15.3 1.6 1.5,1.6 <0.001
Mild PIH 10,639 1,384 13.0 1.3 1.3,1.4 <0.001
Severe PIH 1,814 453 25.0 2.5 2.3,2.8 <0.001
HELLP 212 79 37.3 3.8 3.2,4.5 <0.001
Eclampsia 32 11 34.4 3.5 2.2,5.7 <0.001
Chronic Hypertension 766 102 13.3 1.4 1.1,1.6 0.002
Chronic hypertension and PIH 477 102 21.4 2.2 1.8,2.6 <0.001
PIH denotes pregnancy induced hypertension, HELLP denotes hemolysis, elevated liver enzymes, low platelets syndrome, HTN denotes 
hypertension, CI denotes Confidence interval.
Table 3: Comparison of stillbirth rates among all births to hypertensive vs. normotensive women, Nova Scotia, 1988–2000.
Total No. Stillbirths Relative Risk 95% CI P value
No. %
Normotensive women 122,855 461 0.4 1.0 - -
All hypertensive women 14,013 73 0.52 1.4 1.1,1.8 0.01
Mild PIH 10,683 44 0.4 1.1 0.8,1.5 0.55
Severe PIH 1,826 12 0.7 1.8 1.0,3.1 0.50
HELLP 214 2 0.9 2.5 0.6,9.9 0.19
Eclampsia 32 0 0.0 - 0.0,41.0 1.00
Chronic Hypertension 773 7 0.9 2.4 1.2,5.1 0.03
Chronic hypertension and PIH 485 8 1.7 4.4 2.2,8.8 <0.001
PIH denotes pregnancy induced hypertension, HELLP denotes hemolysis, elevated liver enzymes, low platelets syndrome, HTN denotes 
hypertension, CI denotes Confidence interval.BMC Pregnancy and Childbirth 2004, 4:17 http://www.biomedcentral.com/1471-2393/4/17
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Stillbirth
Table 3 summarizes the crude relationships between
hypertension in pregnancy and stillbirth. There was an
increased risk of stillbirth among women with any hyper-
tensive disorder (RR 1.4, 95% CI 1.1,1.8) and among
women with pregnancies complicated by chronic
hypertension (RR 2.4, 95% CI 1.2,5.1) or chronic hyper-
tension with superimposed PIH (RR 4.4, 95% CI 2.2,8.8),
compared with normotensive pregnancies.
After controlling for potential confounders, women with
any hypertensive disorder were 1.4 (95% CI 1.1,1.8, P =
.02) times more likely to have a stillbirth as compared
with normotensive women (Table 4). Women with pre-
existing hypertension were 3.2 (95% CI 1.9,5.4, P < .001)
times more likely to have a stillbirth as compared with
normotensive women.
Twin pregnancy modified the effect of gestational hyper-
tension with or without proteinuria on small for gesta-
tional age (Table 5). A woman with a singleton pregnancy
who had gestational hypertension without proteinuria
had a 1.5 fold increase in risk of SGA compared with a
woman with a normotensive singleton pregnancy. A
woman with a twin pregnancy had a 4.7 fold increase in
risk of SGA, but the woman with gestational hypertension
without proteinuria and a twin pregnancy had a less than
expected increase in risk of SGA (1.5 × 4.7 × 0.7 = 4.9 as
opposed to 1.5 × 4.7 = 7.1) i.e., the combined effect of a
twin pregnancy and gestational hypertension without
proteinuria was less than what would be expected under a
multiplicative (logistic) model. Similarly, a woman with
gestational hypertension with proteinuria and a twin
pregnancy had a less than expected increase in risk of SGA
(5.2 compared to 17.4). A woman with pre-existing
hypertension who smoked had a less than expected
increase in risk of SGA (4.4 compared to 7.3). A woman
with gestational hypertension without proteinuria and
who smoked had a greater than expected increase in risk
of stillbirth (2.8 compared to 1.1).
Discussion
This large population-based cohort study examined the
magnitude of the risks of small for gestational age and
stillbirth in women with hypertension in pregnancy.
Hypertensive disorders in pregnancy had a significant
effect on rates of SGA after adjusting for potential con-
founders. Pre-existing hypertension had a significant
effect on stillbirth rates after adjusting for potential con-
founders. Modification of the effect of hypertension on
SGA and stillbirth was observed among women who also
had a twin pregnancy or were also smokers.
The rate of hypertensive disorders in pregnancy in this
population (10.1%, 95% CI 10.0,10.3) was similar to that
reported in the literature (10–16%). The rate of mild PIH
in this population was 7.7%, compared with 6–7% in the
literature. The rate of severe PIH (1.3%), HELLP (0.2%)
and eclampsia (0.02%) were lower than expected (5–6%).
The rate of pre-existing hypertension (0.6%) and pre-
existing hypertension with superimposed PIH (0.4%)
were lower than expected (3–5% and 0.8–1.3%, respec-
tively) [25,26]. These differences in rates from what is
expected from the published literature may be explained
by the fact that most previous studies were conducted in
high-risk populations in referral hospitals. Differences
Table 4: Effect of hypertensive disorders in pregnancy on small for gestational age (< 10th percentile) and stillbirth, Nova Scotia, 1988–
2000.
Crude Adjusted
Odds ratio 95% CI P value Odds ratio 95% CI P value
Small for gestational age*
Normotensive women 1.0 - - 1.0 - -
Hypertensive women (any type) 1.6 1.5,1.6 <0.001 1.8 1.7,1.9 <0.001
Gestational hypertension without proteinuria 1.3 1.3,1.4 <0.001 1.5 1.4,1.6 <0.001
Gestational hypertension withproteinuria 2.7 2.5,2.9 <0.001 3.3 3.0,3.9 <0.001
Pre-existing hypertension 1.7 1.5,1.9 <0.001 2.5 2.1,2.9 <0.001
Stillbirth**
Normotensive women 1.0 - - 1.0 - -
Hypertensive women (any type) 1.4 1.1,1.8 0.01 1.4 1.1,1.8 0.02
Gestational hypertension without proteinuria 1.1 0.8,1.5 0.55 1.1 0.8,1.5 0.60
Gestational hypertension with proteinuria 1.8 1.0,3.1 0.03 1.6 0.9,2.9 0.08
Pre-existing hypertension 3.2 1.9,5.3 <0.001 3.2 1.9,5.4 <0.001
CI denotes Confidence interval. * Adjusted for smoking, maternal age, gestational diabetes, pre-existing diabetes, maternal anemia, nulliparity, 
marital status, drug abuse, prepregnancy weight, weight gain, antenatal steroids, twins and infant sex. ** Adjusted for smoking, maternal 
autoantibodies, maternal age, pre-existing diabetes, maternal anemia,prepregnancy weight and twins.BMC Pregnancy and Childbirth 2004, 4:17 http://www.biomedcentral.com/1471-2393/4/17
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between our study findings and those from other popula-
tion-based studies [12-20] may be due to potential differ-
ences in population characteristics, and clinical practice
factors including quality of diagnostic information. Our
study also identified maternal characteristics previously
known to be associated with hypertensive disorders in
pregnancy, including nulliparity [25], older age [27], dia-
betes [28], twin pregnancy [29] and smoking [30].
Small for gestational age is a more appropriate measure of
fetal growth than birthweight alone. Our study evaluated
birthweight for gestational age and gender among live
births to normotensive and hypertensive pregnancies
using a recent population-based Canadian reference [21].
Women with any hypertensive disorder, gestational
hypertension with or without proteinuria, and pre-exist-
ing hypertension were at a significantly higher risk of hav-
ing a SGA infant (relative risk 1.8, 1.5, 3.3, and 2.5,
respectively). The risk of SGA was higher among hyperten-
sive women with a twin pregnancy. Similar patterns in risk
for SGA have been seen in other populations [13,14,16].
Women with any hypertensive disorder and pre-existing
hypertension were at significantly higher risk of stillbirth
compared with women having normotensive pregnancies
(RR 1.4 and 3.2, respectively). Similarities in risk for fetal
mortality between women with gestational hypertension
with or without proteinuria and women who were nor-
motensive in pregnancy have been reported elsewhere
[31].
Chance and confounding are unlikely explanations for
the results of our study, because of the large study size,
and adjustment for potential confounders using logistic
regression. This study was not able to correct for the
degree of blood pressure control, which may have an
effect on fetal growth. While retrospective studies in gen-
eral are limited by the reliability of data, information in
the Nova Scotia Atlee Perinatal Database is of high qual-
ity. Routine data checks and edits are made at the time of
data collection, and validation [32] and reabstraction
studies attest to the quality of the data in this large clinical
database. Our study was limited by the definitions for
hypertensive disorders in pregnancy used by the Nova
Scotia Atlee Perinatal Database, and while these defini-
tions are not exactly the same as commonly used defini-
tions, they approximate definitions proposed by the
Canadian Hypertension Society and other organizations
[4]. The number of comparisons carried out requires that
P values associated with the results be interpreted with
caution.
Table 5: Effect of hypertensive disorders in pregnancy on small for gestational age (< 10th percentile) and stillbirth, with modeling of 
effect-modification by twin pregnancy and maternal smoking, Nova Scotia, 1988–2000.
Adjusted
Odds ratio 95% CI P value
Small for gestational age
Normotensive women 1.0 - -
Gestational hypertension without proteinuria 1.5 1.4,1.6 <0.001
Gestational hypertension with proteinuria 3.7 3.3,4.1 <0.001
Pre-existing hypertension 2.5 2.1,3.0 <0.001
Twins 4.7 4.3,5.2 <0.001
Gestational hypertension without proteinuria × twins 0.7 0.6,0.9 0.01
Gestational hypertension with proteinuria × twins 0.3 0.2,0.4 <0.001
Pre-existing hypertension × twins 0.7 0.3,1.4 0.29
Smoking 2.9 2.8,3.0 <0.001
Gestational hypertension without proteinuria × smoking 1.0 0.9,1.2 0.96
Gestational hypertension with proteinuria × smoking 0.9 0.7,1.1 0.28
Pre-existing hypertension × smoking 0.6 0.4,0.8 0.002
Stillbirth
Normotensive women 1.0 - -
Gestational hypertension without proteinuria 0.8 0.5,1.2 0.24
Gestational hypertension with proteinuria 1.4 0.6,2.9 0.42
Pre-existing hypertension 3.5 2.0,6.2 <0.001
Smoking 1.4 1.2,1.7 <0.001
Gestational hypertension without proteinuria × smoking 2.5 1.3,4.7 0.006
Gestational hypertension with proteinuria × smoking 1.8 0.4,5.3 0.33
Pre-existing hypertension × smoking 0.6 0.1,2.5 0.43
CI denotes Confidence interval.** Adjusted for smoking, maternal age, gestational diabetes, pre-existing diabetes,maternal anemia, nulliparity, 
marital status, drug abuse, prepregnancy weight,weight gain, antenatal steroids, twins and infant sex. ** Adjusted for smoking, maternal 
autoantibodies, maternal age, pre-existing diabetes, maternal anemia, prepregnancy weight and twins.BMC Pregnancy and Childbirth 2004, 4:17 http://www.biomedcentral.com/1471-2393/4/17
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Conclusions
This population-based cohort study demonstrates that
women with hypertensive disease in pregnancy are at sig-
nificantly higher risk of having pregnancies complicated
by small for gestational age (<10th percentile) and still-
birth in comparison with women with normotensive
pregnancies. Twin gestation and smoking were important
modifiers of the effect of hypertension on SGA and still-
birth. This study allowed the quantification of risks of
adverse outcomes in women with pregnancies compli-
cated by hypertension, confirming associations in the
published literature and allowing appropriate counseling
and monitoring in the management of these women, as
well as providing baseline risks which may be used in
future intervention studies.
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